Abstract: The present invention provides a fluorescent molecular probe for efficient fluorescent detection (visualization) of tumors or for implementing fluorescent detection and photodynamic treatment, more specifically, the present invention provides a macromolecular fluorescent molecular probe for fluorescent detection of tumor, comprising a complex comprising a fluorescent molecule and a biocompatible macromolecule.

Abstract: The present invention provides a polymeric agent which can incorporate a large amount of a drug, accumulate selectively in a tumor site, and has a molecular size of more than that for renal excretion. A metalloporphyrin derivative (such as zinc protoporphyrin) is associated with a styrene-maleic acid copolymer via non-covalent bond to give a SMA micelle complex, allowing provision of a polymeric pharmaceutical agent for treatment of cancer with a large amount of the drug incorporated. The SMA micelle complex can be produced by a method, wherein the metalloporphyrin derivative reacts with the styrene-maleic acid copolymer in the absence of a condensation agent under an alkaline condition, solubilized, adjusted to have a pH of 6-8, and subjected to a procedure for separating a polymer component to recover the micelle complex component for the polymeric pharmaceutical agent.

Abstract: An antitumor agent, which is a combination of an oxidoreductase, such as xanthine oxidase chemically conjugated to a polymer such as poly ethylene glycol, for initial administration and accumulation in the tumor tissue followed by administration and of a substrate for the oxidoreductase which releases reactive oxygen species. Improved tumor selective cytotoxic activity results.

Abstract: A method for treatment of viral infections which comprises administering to the patients being suffering from said viral infections an effective amount of one or more substances selected from the group consisting of nitric oxide scavengers and nitric oxide synthase inhibitors. Said method for treatment of viral infections is useful in viral infections induced by influenza virus, herpes virus, hepatitis virus, cytomegalovirus, human immunodeficiency virus, etc.

Abstract: Antihypertensive agents containing as its active ingredient the 4-amino-6-hydroxypyrazolo ?3,4-d!pyrimidine(AHPP) or its derivatives represented by the general formula (I) below. ##STR1## where R is hydrogen atom, alkyl group or aryl group.AHPP can be chemically synthesized by a reaction of 3-amino-4-cyanopyrazole and urea.The antihypertensive agents of the present invention show a mild and reliable blood pressure lowering activity, and have a different mode of action from currently available antihypertensive agents.

Abstract: A composite reagent, for a veterinary diagnostic test, which contains a color reagent substance to produce a color by reacting with either one or both of magnesium (Mg) ions and calcium (Ca) ions, a polyoxyethylene alkylphenyl ether, and a masking agent for interfering metal ions in a urine of an animal other than the Mg ions and the Ca ions.

Abstract: (1) The imidazoline derivative represented by the following general formula (1) ##STR1## where R.sup.1 is a substituent endowed with water solubility or fat solubility, particularly carboxyl group or carboxymethoxy group or a pharmaceutically acceptable salt thereof, (2) The method for producing the above-mentioned compound, and (3) A therapeutic agent containing as its active ingredient the above-mentioned imidazoline derivative or an imidazoline derivative wherein R.sup.1 indicated in the formula (1) is hydrogen atom. The imidazoline derivative set forth under (1) above is a novel substance; and this compound itself and its derivative having R.sup.1 as indicated in the general formula (1) is hydrogen atom are useful as a therapeutic agent for treatment of shock from the fall in blood pressure by virtue of their ability to remove excess NO which is the vascular endothelium-derived relaxing factor (EDRF).

Abstract: A composition for oral administration to cancer patients includes a neocarzinostatin derivative and from 0.1 and 100 ml per mg of the neocarzinostatin derivative of at least one fatty acid glyceride which has from 6 to 20 carbon atoms and which is noniodized. The composition is effective in the treatment of cancer by oral administration, including a solid cancerous tumor.

Abstract: The invention provides a superoxide dismutase derivative of the general formula[SOD][Z]wherein [SOD] represents a superoxide dismutase having 1 to 22 or 24 groups each derived from an amino groups by removal of one hydrogen atom in lieu of amino groups; [Z] represents a monovalent copolymer group, constituting units of which are a group of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each represents a hydrogen atom or a residue derived by a removal of a hydroxyl group from an alkanol of 1 to 8 carbon atoms, an ethylene glycol monoalkyl ether containing an alkyl moiety of 1 to 4 carbon atoms or a glycerin dialkyl ether containing alkyl moieties of 1 to 4 carbon atoms, provided that either R.sup.1 or R.sup.2 and either R.sup.3 or R.sup.4 each represents a hydrogen atom, and a residue derived from the group of the above-mentioned formula by removal of OR.sup.1, OR.sup.2, OR.sup.3 or OR.sup.4 group from one of its COOR.sup.1, COOR.sup.2, COOR.sup.3 and COOR.sup.

Abstract: The invention provides a superoxide dismutase derivative of the general formula[SOD][Z].sub.nwherein [SOD] represents a superoxide dismutase having 1 to 22 or 24 groups each derived from an amino group by removal of one hydrogen atom in lieu of amino groups; [Z] represents a monovalent copolymer group, constituting units of which are a group of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each represents a hydrogen atom or a residue derived by removal of a hydroxyl group from an alkanol of 1 to 8 carbon atoms, an ethylene glycol monoalkyl ether containing an alkyl moiety of 1 to 4 carbon atoms or a glycerin dialkyl ether containing alkyl moieties of 1 to 4 carbon atoms, provided that either R.sup.1 or R.sup.2 and either R.sup.3 or R.sup.4 each represents a hydrogen atom, and a residue derived from the group of the above-mentioned formula by removal of OR.sup.1, OR.sup.2, OR.sup.3 or OR.sup.4 group from one of its COOR.sup.1, COOR.sup.2, COOR.sup.3 and COOR.sup.

Abstract: Method of treating a tumor in a mammal comprises administering to said mammal an effective anti-tumor amount of proteases originating from microorganisms.Method of treating a tumor in a mammal comprises administering to said mammal an effective anti-tumor amount of a protease originating from a microorganism which protease is chemically modified by one of the following procedures:(a) coupling with a saccharide,(b) introduction of a hydrophobic polymeric group,(c) alteration of electric charge of the protein surface,(d) conjugation with a low molecular weight anti-tumor agent of molecular weight less than 2,000,(e) formation of dimer or oligomer by cross-linking of protease molecules,(f) conjugation with a synthetic polycation,(g) conjugation with a synthetic polyanion, and(h) combination of the above-mentioned procedures.

Abstract: Substantially pure neocarzinostatin anticancer agents have the formula (A):(SMA)--(NCS)--(SMA) (A)wherein (NCS) is a divalent neocarzinostatin residue and (SMA) comprises the monovalent residue of a partially half-esterified styrene-maleic acid copolymer having a weight-average molecular weight of from 800 to 2,500, said (NCS) residue being bonded to said (SMA) residues via amide linkages formed between primary amino groups of the neocarzinostatin molecule and carbonyl groups of the partially half-esterified styrene-maleic acid copolymer.

Abstract: Substantially pure neocarzinostatin anticancer agents have the formula (A):(SMA)-(NCS)-(SMA) (A)wherein (NCS) is a divalent neocarzinostatin residue and (SMA) comprises the monovalent residue of a styrene-maleic acid copolymer having a weight-average molecular weight of from 800 to 2,500, said (NCS) residue being bonded to said (SMA) residues via amide linkages formed between primary amino groups of the neocarzinostatin molecule and carbonyl groups of the styrene-maleic acid copolymer.

Abstract: Novel neocarzinostatin anticancer agents have the formula:(SMA)--(NCS)wherein (NCS) is a neocarzinostatin residue, n is an integer ranging from 1 to 35, and (SMA) comprises the residue of a half-esterified styrene-maleic acid copolymer having an average molecular weight of from 1,000 to 10,000, said half-esterified styrene-maleic acid copolymer comprising (i) styrene residues, (ii) maleic acid residues covalently bonded to (NCS), (iii) free maleic acid residues, and (iv) half-esterified maleic acid residues, and further wherein the total amount of said residues (ii) and (iii) ranges from an average of 0.1 per molecule to 60 mole % of said (SMA).